Evaxion Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-22.13	-23.17	-24.53	-15.02	-11.2	Upgrade
Other Operating Activities	4.43	-2.61	2.6	2.58	4.18	Upgrade
Operating Cash Flow	-17.69	-25.77	-21.93	-12.44	-7.02	Upgrade
Capital Expenditures	-0.09	-0.29	-1.36	-0.18	-0.06	Upgrade
Change in Investments	-0.01	0.02	0.03	-0.21	-0.01	Upgrade
Investing Cash Flow	-0.09	-0.27	-1.33	-0.39	-0.07	Upgrade
Share Issuance / Repurchase	11.32	0.43	50.09	8.89	9.43	Upgrade
Debt Issued / Paid	-0.63	7.43	-0.29	-0.07	0.08	Upgrade
Financing Cash Flow	10.69	7.85	49.81	8.82	9.51	Upgrade
Exchange Rate Effect	-0.51	-0.79	-0.21	0.29	-0.3	Upgrade
Net Cash Flow	-7.09	-18.19	26.54	-4.01	2.42	Upgrade
Free Cash Flow	-17.78	-26.07	-23.29	-12.62	-7.08	Upgrade
Free Cash Flow Margin	-24353.42%	-	-	-	-	Upgrade
Free Cash Flow Per Share	-6.43	-11.23	-12.13	-6.66	-3.74	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).